|
1
|
Birebent B, Lorho R, Lechartier H, de
Guibert S, Alizadeh M, Vu N, Beauplet A, Robillard N and Semana G:
Suppressive properties of human CD4+CD25+
regulatory T cells are dependent on CTLA-4 expression. Eur J
Immunol. 34:3485–3496. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Pedicord VA, Montalvo W, Leiner IM and
Allison JP: Single dose of anti-CTLA-4 enhances CD8+
T-cell memory formation, function, and maintenance. Proc Natl Acad
Sci USA. 108:266–271. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Takahashi T, Tagami T, Yamazaki S, Uede T,
Shimizu J, Sakaguchi N, Mak TW and Sakaguchi S: Immunologic
self-tolerance maintained by CD25(+)CD4(+) regulatory T cells
constitutively expressing cytotoxic T lymphocyte-associated antigen
4. J Exp Med. 192:303–310. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Liu H, Hu B, Xu D and Liew FY:
CD4+CD25+ regulatory T cells cure murine
colitis: The role of IL-10, TGF-beta and CTLA4. J Immunol.
171:5012–5017. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Houghton AN and Guevara-Patino JA: Immune
recognition of self in immunity against cancer. J Clin Invest.
114:468–471. 2004. View
Article : Google Scholar : PubMed/NCBI
|
|
6
|
Nishikawa H and Sakaguchi S: Regulatory T
cells in tumor immunity. Int J Cancer. 127:759–767. 2010.PubMed/NCBI
|
|
7
|
Andreo P, Burns DT, Hohlfeld K, Huq MS,
Kanai T, Laitano F, Smyth VG and Vynckier S: Absorbed dose
determination in external beam radiotherapy: An international code
of practice for dosimetry based on standards of absorbed dose to
waterTech Report Series No. 398. International Atomic Energy
Agency; Vienna: pp. 1–183. 2006
|
|
8
|
Son CH, Bae JH, Shin DY, Lee HR, Yang K
and Park YS: Antitumor effect of dendritic cell loaded ex vivo and
in vivo with tumor-associated antigens in lung cancer model.
Immunol Invest. 43:447–462. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Kim KW, Kim SH, Shin JG, Kim GS, Son YO,
Park SW, Kwon BH, Kim DW, Lee CH, Sol MY, et al: Direct injection
of immature dendritic cells into irradiated tumor induces efficient
antitumor immunity. Int J Cancer. 109:685–690. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Facciabene A, Motz GT and Coukos G:
T-regulatory cells: Key players in tumor immune escape and
angiogenesis. Cancer Res. 72:2162–2171. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Voena C and Chiarle R: Advances in cancer
immunology and cancer immunotherapy. Discov Med. 21:125–133.
2016.PubMed/NCBI
|
|
12
|
Sansom DM and Walker LS: The role of CD28
and cytotoxic T-lymphocyte antigen-4 (CTLA-4) in regulatory T-cell
biology. Immunol Rev. 212:131–148. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Niezgoda A, Niezgoda P and Czajkowski R:
Novel approaches to treatment of advanced melanoma: A review on
targeted therapy and immunotherapy. BioMed Res Int.
2015:8513872015. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Calabrò L, Ceresoli GL, di Pietro A,
Cutaia O, Morra A, Ibrahim R and Maio M: CTLA4 blockade in
mesothelioma: Finally a competing strategy over cytotoxic/target
therapy? Cancer Immunol Immunother. 64:105–112. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Staveley-O'Carroll K, Sotomayor E,
Montgomery J, Borrello I, Hwang L, Fein S, Pardoll D and Levitsky
H: Induction of antigen-specific T cell anergy: An early event in
the course of tumor progression. Proc Natl Acad Sci USA.
95:1178–1183. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
van Elsas A, Hurwitz AA and Allison JP:
Combination immunotherapy of B16 melanoma using anti-cytotoxic T
lymphocyte-associated antigen 4 (CTLA-4) and granulocyte/macrophage
colony-stimulating factor (GM-CSF)-producing vaccines induces
rejection of subcutaneous and metastatic tumors accompanied by
autoimmune depigmentation. J Exp Med. 190:355–366. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Dong H, Strome SE, Salomao DR, Tamura H,
Hirano F, Flies DB, Roche PC, Lu J, Zhu G, Tamada K, et al:
Tumor-associated B7-H1 promotes T-cell apoptosis: A potential
mechanism of immune evasion. Nat Med. 8:793–800. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Yang YF, Zou JP, Mu J, Wijesuriya R, Ono
S, Walunas T, Bluestone J, Fujiwara H and Hamaoka T: Enhanced
induction of antitumor T-cell responses by cytotoxic T
lymphocyte-associated molecule-4 blockade: The effect is manifested
only at the restricted tumor-bearing stages. Cancer Res.
57:4036–4041. 1997.PubMed/NCBI
|
|
19
|
Paradis TJ, Floyd E, Burkwit J, Cole SH,
Brunson B, Elliott E, Gilman S and Gladue RP: The anti-tumor
activity of anti-CTLA-4 is mediated through its induction of IFN
gamma. Cancer Immunol Immunother. 50:125–133. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Fecci PE, Ochiai H, Mitchell DA, Grossi
PM, Sweeney AE, Archer GE, Cummings T, Allison JP, Bigner DD and
Sampson JH: Systemic CTLA-4 blockade ameliorates glioma-induced
changes to the CD4+ T cell compartment without affecting
regulatory T-cell function. Clin Cancer Res. 13:2158–2167. 2007.
View Article : Google Scholar : PubMed/NCBI
|
